Dapagliflozin Reduces Liver Fat in Type 2 Diabetes Independent of Weight Loss — Over 12 months, dapagliflozin produced a significantly greater reduction in liver fat fraction compared to placebo (-3.
Patiromer Shows No Added Benefit Over Placebo for Acute Hyperkalaemia in Emergency Settings — In a randomised, double-blind, placebo-controlled trial across 16 US emergency departments, patiromer added to standard combination therapy produced no statistically significant improvement in net clinical benefit or potassium reduction at 6 hours compared with placebo (-0.
Tongxinluo Capsule Increases Coronary Plaque Fibrous Cap Thickness Over 12 Months — In patients with acute coronary syndrome, adding Tongxinluo capsule to standard statin therapy produced a meaningfully greater increase in minimum fibrous cap thickness compared to placebo at 12 months (115.